- Case report
- Open Access
Invasive Aspergillus fumigatus infection after Plasmodium falciparum malaria in an immuno-competent host: Case report and review of literature
© Eckerle et al; licensee BioMed Central Ltd. 2009
- Received: 18 April 2009
- Accepted: 20 July 2009
- Published: 20 July 2009
Invasive fungal infection is rarely reported in association with malaria, even though malaria-associated inhibition of phagocyte function is a well-known condition. Invasive aspergillosis is frequently found in severely immuno-compromised patients but not in healthy individuals. Here, a case of pulmonary invasive aspergillosis in a previously healthy patient with severe P. falciparum malaria is presented, who was successfully treated with voriconazol and caspofungin. This is the first survival of malaria-associated invasive aspergillosis.
- Falciparum Malaria
- Invasive Aspergillosis
There is strong evidence that malaria can lead to altered immune response via modulation of both humoral and cell-mediated immunity. Therefore, Plasmodium falciparum malaria with subsequent transient immunosuppression can lead to opportunistic infections in previously immunocompetent patients .
Aspergillosis (Aspergillus spp.) is a major cause of morbidity and mortality in immuno-suppressed hosts, such as patients with haematological malignancies and transplant recipients. Aspergillus spp. is found ubiquitously in the environment worldwide and reaches the alveoli by airborne transmission. In healthy persons, the spores are eliminated by mucociliary clearance and pulmonary macrophages. Although infection in healthy individuals can occur, invasive aspergillosis is extremely uncommon in immuno-competent hosts. There are only four reported cases of invasive aspergillosis complicating falciparum malaria in immuno-competent hosts, all with fatal outcome [2–4].
A 58-year old Caucasian man returned from an 11-day vacation in the Dominican Republic. He had no previous medical history and no malaria prophylaxis was taken.
Six days after return, he developed a fever of up to 40.5°C and dark-coloured watery diarrhoea with nausea and vomiting. His general practitioner suggested a viral infection and treated him with ibuprofen. The fever remained high and on the 7th day of illness, his general condition deteriorated. On presentation at the hospital, he additionally was complaining of pain upon swallowing.
On admission, he was sleepy, but fully oriented, afebrile and pale. No signs of meningitis were found. The lungs were clear and the heart sounds normal. BP was 150/85 mmHg and the pulse rate 95/min. Blood films showed P. falciparum with a parasitaemia of 9.5%. Initial laboratory results were Hb 14.6 g/dl, WBC 8.14/nl, PLT 12/nl, CRP 162.8 mg/l (normal range < 5 mg/l), creatinine 6.09 mg/dl, urea 208 mg/dl, LDH 805 U/l, GOT 69 U/l, GPT 197 U/l. Blood culture, urine culture and serology for hepatitis A, B, C and HIV were negative. Chest x-ray and ultrasound were unremarkable except for mild hepatosplenomegaly. Pharyngitis sicca was diagnosed by the ENT consultant.
Treatment with quinine i.v. was initiated with a loading dose of 7.0 mg/kgBW and continued at a rate of 10 mg/kgBW every eight hours for four hours over 10 days. Parasitaemia decreased to 2.7% within three days and was cleared by day five. He was put on intermittent hemodialysis after developing acute renal failure. Antibiotic coverage with imipenem was started.
On day 5 of hospitalization, respiration deteriorated and the patient was intubated. The chest x-ray revealed patchy infiltrates of the upper left lobe and on bronchoscopy bronchial obstruction with viscous mucus was seen. This was cleared and in the material obtained Aspergillus fumigatus was cultured abundantly. The circulating antigens of 0.8 remained below the positive cut-off of 1.0 given by the laboratory. The anti-Aspergillus antibody titre remained below the positive cut-off of 1:160 – 1:320. Therapy with voriconazol and caspofungin was started immediately.
Aspergillosis, in particular the invasive course of the disease, is only seen in patients with severe immuno-suppression and has a very poor prognosis. In individuals without severe immuno-suppression, invasive fungal infections are extraordinarily rare. Till date invasive aspergillosis during P. falciparum malaria has only been described in four cases, none of which survived [2–4]. Two other cases of invasive fungal infections associated with P. falciparum malaria had disseminated candidiasis and cryptococcal meningitis [5, 6].
Falciparum malaria can lead to suppression of both humoral and cell-mediated immunity. Humoral immunity is impaired through reduced production of specific antibodies, while cell-mediated immunity is modulated by inhibition of dendritic cells, which is crucial as they initiate all adaptive and several innate immune responses, and also impairment of T cell and macrophage function plays a role [1, 7, 8].
Inhibition of key enzymes involved in oxidative burst by the malaria-pigment haemozoin seems to be one of the most important mechanisms contributing to the disruption of macrophage function. Both in vitro and in vivo studies showed that large proportions of resident macrophages as well as circulating monocytes and leucocytes are loaded with haemozoin and consequently lose their ability to phagocytose and kill ingested germs such as fungi . Especially the latter seems to play a role in invasive fungal infection, because pulmonary macrophages are the major line of defence for Aspergillus spp., as they are eliminating spores from the lungs . The central role of phagocytes in the defence of fungal infections is underlined by the following observation: In patients suffering from chronic granulomatous disease, an inherited immunodeficiency due to a NADPH oxidase defect, Aspergillus spp. is the most frequent fungal pathogen and pneumonia the major cause of death, because here phagocytes fail to generate reactive antimicrobial oxidants which impairs oxidative burst . The malaria-induced inhibition of macrophages seems to appear late in the acute phase of the disease and persists for various lengths of time after recovery, as haemozoin stays in the affected macrophages for several months . While haemozoin induces functional inhibition of macrophages, the availability of macrophages at the site of infection (in the case presented the lung) is questionable, as during malaria infection macrophages in the blood are likely concentrated where parasitized red blood cells are concentrated. These organs include spleen, liver and bone marrow, but not the lung.
In the case presented, as in the four other published cases, inhibition of macrophages leading to aspergillosis was most likely malaria-associated as no other cause was found. Other mechanisms such as inhibition of humoral and antigen-specific T-cells response are unlikely to be a strong factor for malaria-induced immunosuppression in the acute phase of the disease in a patient without prior malaria infection or semi-immunity. Prolonged and profound neutropenia, the single most important and common risk factor for invasive aspergillosis, was neither present in this case nor in the patients published.
In contrast to the previously described fatal cases, no other malaria-related complication such as cerebral malaria or ARDS was seen in this case, but in two of the other published cases. The patient responded quickly to malaria treatment with rapid clearance of parasites. Invasive aspergillosis became clinically apparent only after malaria parasites had been eradicated and after the patient had started to improve already which is not surprising, as it is known that malaria-induced immunosuppression occurs late in the acute phase of the disease. Whether the initial presentation of pain upon swallowing was already related to the beginning of the Aspergillus infection is not clear. The Aspergillus antigen detection with a magnitude below 1.0 was interpreted as negative despite extensive Aspergillus growth in the culture. However, in many settings now a positive cut-off of 0.5 is used, therefore the maximal antigen magnitude of 0.8, which was measured after the positive culture result, would meet the criteria for a positive result. There are also several studies which showed that galactomannan ELISA is not as sensitive in invasive aspergillosis as anticipated . The negative anti-Aspergillus antibody titre could be an additional marker for severely impaired immune response to Aspergillus due to malaria-induced immunosuppression.
Voriconazole is a triazol antifungal that is considered first-line-treatment for invasive aspergillosis . Because of the progressive and life-threatening course of the disease, caspofungin, which belongs to the echinocandins, a new class of anti-fungals, was administered additionally. Early recognition and immediate treatment with two potent anti-fungals may have been the key to successful treatment of invasive aspergillosis and the first described survival of a patient.
As malaria mostly occurs in low-resource countries with limited access to diagnostic tools, underreporting of fungal disease complicating malaria may be a problem. With only four cases reported so far, the incidence seems to be very low, however. For practical purposes invasive fungal disease should be considered in malaria patients deteriorating after successful anti-malarial treatment. This case shows that early recognition and immediate treatment in principle can avert a fatal outcome.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Gerd Pluschke, Department Medical Parasitology & Infection Biology, Swiss Tropical Institute, Basle, for his advice on the immunological processes in malaria-induced immunosuppression and John Moyers, Institute of Pathology, Heidelberg, for processing of the histological images.
- Wykes MN, Good MF: What really happens to dendritic cells during malaria?. Nat Rev Microbiol. 2008, 6: 864-70. 10.1038/nrmicro1988.PubMedGoogle Scholar
- Wilson AP, Wright S, Bellingan G: Disseminated fungal infection following falciparum malaria. J Infect. 2000, 40: 202-4. 10.1053/jinf.2000.0637.View ArticlePubMedGoogle Scholar
- Ruhnke M, Eichenauer E, Searle J, Lippek F: Fulminant tracheobronchial and pulmonary aspergillosis complicating imported Plasmodium falciparum malaria in an apparently immunocompetent woman. Clin Infect Dis. 2000, 30: 938-40. 10.1086/313819.View ArticlePubMedGoogle Scholar
- Hocqueloux L, Bruneel F, Pages CL, Vachon F: Fatal invasive aspergillosis complicating severe Plasmodium falciparum malaria. Clin Infect Dis. 2000, 30: 940-2. 10.1086/313814.View ArticlePubMedGoogle Scholar
- Soesan M, Kager PA, Leverstein-van Hall MA, van Lieshout JJ: Coincidental severe Plasmodium falciparum infection and disseminated candidiasis. Trans R Soc Trop Med Hyg. 1993, 87: 288-9. 10.1016/0035-9203(93)90131-9.View ArticlePubMedGoogle Scholar
- Ashiru JO, Akang EE: Cryptococcal meningitis with malaria. A case report. Mycopathologia. 1994, 127: 15-7. 10.1007/BF01104006.View ArticlePubMedGoogle Scholar
- Urban BC, Todryk S: Malaria pigment paralyzes dendritic cells. J Biol. 2006, 5: 4-10.1186/jbiol37.PubMed CentralView ArticlePubMedGoogle Scholar
- Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM, Jansen-Rosseck R, Bienzle U: Immune response in patients during and after Plasmodium falciparum infection. J Infect Dis. 1990, 161: 1025-8.View ArticlePubMedGoogle Scholar
- Schwarzer E, Alessio M, Ulliers D, Arese P: Phagocytosis of the malarial pigment, hemozoin, impairs expression of major histocompatibility complex class II antigen, CD54, and CD11c in human monocytes. Infect Immun. 1998, 66: 1601-6.PubMed CentralPubMedGoogle Scholar
- Schaffner A, Douglas H, Braude A: Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest. 1982, 69: 617-31. 10.1172/JCI110489.PubMed CentralView ArticlePubMedGoogle Scholar
- Berg van den JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, Espanol T, Fischer A, Kurenko-Deptuch M, Mouy R, Petropoulou T, Roesler J, Seger R, Stasia MJ, Valerius NH, Weening RS, Wolach B, Roos D, Kuijpers TW: Chronic granulomatous disease: the European experience. PLoS One. 2009, 4: e5234-10.1371/journal.pone.0005234.PubMed CentralView ArticlePubMedGoogle Scholar
- Pinel C, Fricker-Hidalgo H, Lebeau B, Garban F, Hamidfar R, Ambroise-Thomas P, Grillot R: Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol. 2003, 41: 2184-6. 10.1128/JCM.41.5.2184-2186.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008, 46: 327-60. 10.1086/525258.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.